Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1^+/- mouse model.

ABSTRACT: Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1^+/- mice, a model of sporadic Parkinson's disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson's phenotype expressed by the B4galnt1^+/- mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 w

SUBMITTER: Chiricozzi E 

PROVIDER: S-EPMC6920361 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature